??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy
- 1 April 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 15 (4), 227-234
- https://doi.org/10.1097/01213011-200504000-00006
Abstract
Objective Large variability exists in the improvement in eft ventricular (LV) function from β-blocker treatment. We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the β1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to β-blocker therapy among heart failure patients. Methods We prospectively enrolled 61 β-blocker naïve patients with systolic heart failure. Patients underwent baseline echocardiography followed by metoprolol CR/XL. The dose was doubled on a biweekly basis up to 200 mg/day or attainment of maximum tolerated dose. Echocardiography was repeated after the patient received the target or highest tolerated dose for 3 months. Results Among patients with the Arg389Arg genotype, ejection fraction (EF) increased from 23±5 to 29±10 (P=0.008). Gly389 carriers did not demonstrate any significant change in EF (22±9 to 23±11; P=0.45). There was a significant between-group difference in EF by genotype (P=0.04). The Arg389Arg genotype was also associated with significantly greater reductions in LV end-diastolic and end-systolic diameters compared to Gly389 carriers. Patients with the Gly49 variant also had a significantly greater reduction in LV end-diastolic diameter compared to Ser49 homozygotes. Multiple regression analysis modeling revealed that the codon 389 polymorphism was a significant predictor of an improvement in EF and both codon 49 and 389 polymorphisms were significant predictors of final LV end-diastolic diameter. Conclusions Heart failure patients with the Arg389Arg genotype and Gly49 carriers had greater improvements in LV remodeling from β-blocker treatment.Keywords
This publication has 30 references indexed in Scilit:
- Heart FailureThe New England Journal of Medicine, 2003
- Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunctionJournal of Cardiac Failure, 2002
- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the international society for heart and lung transplantation endorsed by the heart failure society of americaJournal of the American College of Cardiology, 2001
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureThe New England Journal of Medicine, 2001
- Differential Effects of β-Blockers in Patients With Heart FailureCirculation, 2000
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failureThe American Journal of Cardiology, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Left Ventricular Remodeling With Carvedilol in Patients With Congestive Heart Failure Due to Ischemic Heart DiseaseJournal of the American College of Cardiology, 1997
- Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockadeJournal of the American College of Cardiology, 1995